News Center

9/24

2024

Haihe Biopharma and Taiho Pharmaceutical Announce the Launch of MET Inhibitor HAIYITAN® Tablets 50mg in Japan

Haihe Biopharma Co., Ltd. (hereinafter “Haihe”) and Taiho Pharmaceutical Co., Ltd. (hereinafter “Taiho”) announced today that the MET inhibitor, HAIYITAN® tablets 50mg (generic name: gumarontinib hydrate), is schedule for launch on October 11, 2024, in Japan.

 

In June 2024, Haihe Biopharma K. K., a fully owned affiliate of Haihe, obtained approval to manufacture and market HAIYITAN in Japan for the treatment of unresectable, advanced or recurrent non-small cell lung cancer with MET exon 14 skipping mutations.

 

HAIYITAN is an oral, small-molecule, receptor-type tyrosine kinase MET inhibitor developed by Haihe. HAIYITAN is expected to inhibit tumor growth by blocking MET phosphorylation and downstream signaling.1 In China, HAIYITAN has been approved by the National Medical Products Administration (NMPA) for manufacturing and marketing in March 2023.

 

Taiho and Haihe, together with Haihe Biopharma K. K., will contribute to patients with non-small cell lung cancer and healthcare professionals by providing HAIYITAN as a new treatment option for non-small cell lung cancer.

 
About Non-Small Cell Lung Cancer with MET exon 14 Skipping Mutations

Primary lung cancer is the second most common malignancy in the world and has the highest mortality rate.2 In Japan, the number of new patients with lung cancer is reported to be more than 120,000/year (2019), and the number of deaths is over 70,000/year (2020).3 The percentage of non-small cell lung cancer among patients with lung cancer in Japan is 88%, and the frequency of MET exon 14 skipping mutations is about 3%.4 Thus, in Japan, the number of patients with MET exon 14 skipping gene mutations positive, unresectable, advanced or recurrent non-small cell lung cancer who are eligible for treatment with HAIYITAN is estimated to be around 1,200/year.

About MET Tyrosine Kinase

MET gene encodes a receptor-type tyrosine kinase. Binding hepatocyte growth factor (HGF), a MET ligand, induces receptor dimerization and autophosphorylation of tyrosine residues in the kinase domain of MET, forming binding sites for various signaling factors. Subsequently, intracellular signaling cascades such as the RAS pathway are activated to stimulate tumor cell growth, migration, invasion, and angiogenesis in cancer.5

Summary of Product Information in Japan

Brand name

HAIYITAN® tablets 50mg

Generic name

Gumarontinib hydrate

Indications

Unresectable, advanced or recurrent non-small cell lung cancer with MET exon 14 skipping mutations

Dosage and administration

Normally, for adults, oral administration in fasting condition of 300mg of gumarontinib once daily. Dosage should be reduced based on the patient’s condition.

Date of manufacturing and marketing approval

June 24, 2024

Date listed in NHI reimbursement price listing

August 15, 2024

Date of initial marketing in Japan

October 11, 2024

NHI reimbursement price

JPY 4,382.30 / tablet

Packaging

PTP Packaging: 24 tablets (8 tablets x 3)

Manufacturer and distributor

Haihe Biopharma K. K.

Distributor

Taiho Pharmaceutical Co., Ltd.

 

About Taiho Pharmaceutical Co., Ltd. (Japan)

Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd. (https://www.otsuka.com/en/), is an R&D-driven specialty pharma focusing on the fields of oncology and immune-related diseases. Its corporate philosophy takes the form of a pledge: “We strive to improve human health and contribute to a society enriched by smiles.” In the field of oncology, in particular, Taiho Pharmaceutical is known as a leading company in Japan for developing innovative medicines for the treatment of cancer, a reputation that is rapidly expanding through their extensive global R&D efforts. In areas other than oncology, as well, the company creates and markets quality products that effectively treat medical conditions and can help improve people’s quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer consumer healthcare products that support people’s efforts to lead fulfilling and rewarding lives. For more information about Taiho Pharmaceutical, please visit https://www.taiho.co.jp/en/

About Haihe Biopharma Co., Ltd.

Haihe Biopharma Co., Ltd is a global, values-based, R&D driven biopharmaceutical leader headquartered in China with operation centers in the US and Japan, and mainly focuses on innovative anti-tumor therapies. The company has the comprehensive capability of drug discovery, development, manufacturing and commercialization, and delivers life-saving therapies to cancer patients in China and around the world. Haihe Biopharma is committed in-house innovation with global perspective management and R&D team. Currently Haihe Biopharma has one approved product Gumarontinib (INN) in China and Japan and several drug candidates. Haihe Biopharma K. K. is a fully owned affiliate of Haihe Biopharma Co., Ltd. and has been introducing a rich pipeline of novel anticancer drugs to contribute the better treatment of patients in Japan.

  1. Ai J, Chen Y, Peng X, et al. Preclinical evaluation of SCC244 (Glumetinib), a novel, potent and highly selective inhibitor of c-Met in MET-dependent cancer models. Mol Cancer Ther. 2018;17(4):751–762
  2. Sung, H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3): p. 209–249.
  3. Cancer information service “Cancer Statistics” of National Cancer Institute as of 12th September 2024 https://ganjoho.jp/reg_stat/statistics/stat/cancer/12_lung.html
  4. Vuong HG, Ho ATN, Altibi AMA, et al. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis. Lung Cancer. 2018;123:76–82.
  5. Tomoyuki Naito, et al. Treatment of Lung Cancer Targeting MET Alterations. Japanese Journal of Lung Cancer. 2021: 61: 273-281
Follow Us
©2020 Haihe Biopharma Co., Ltd.
All Rights Reserved 沪ICP备12016151号-1